Trastuzumab: Herceptin moving to Herzuma
On 1 December 2023, Herzuma, the biosimilar trastuzumab, will be funded. This will make trastuzumab available to treat more people.
On this page
The Herceptin brand of trastuzumab is currently funded to treat early and metastatic breast cancer. Following a competitive procurement process, Pharmac will be funding the biosimilar trastuzumab Herzuma from 1 December 2023.
This has allowed us to widen access for trastuzumab to treat people with gastric, gastro-oesophageal junction, and oesophageal cancer.
We're also now allowing people to take "treatment holidays" from both trastuzumab and pertuzumab. Pertuzumab is another treatment for metastatic breast cancer and is funded for use with trastuzumab.
By 1 June 2024, anyone taking Herceptin will need to have moved to Herzuma.
1 October 2023 - People taking trastuzumab can take "treatment holidays".
1 December 2023 - Herzuma listed in the Pharmaceutical Schedule. Everyone starting trastuzumab will be started on Herzuma.
1 June 2024 - Herceptin delisted from the Schedule. Everyone must be moved to Herzuma (unless there are exceptional clinical circumstances)
If you have questions about this change, email firstname.lastname@example.org